DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Seladelpar
Seladelpar
Advances in Hepatology
A61p1/16 (2006.01) A61p3/00 (2006.01) Km, Ml, Mr, Ne, Sn, Td, Tg)
The Opportunities and Challenges of Peroxisome Proliferator-Activated Receptors Ligands in Clinical Drug Discovery and Development
Highlights in Primary Biliary Cholangitis from the EASL 2020 Digital International Liver Congress, the ACG 2020 Virtual Annual Scientific Meeting, And
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases 1 2 3 4 5 Keith D
Lessons from Liver-Specific PPAR-Null Mice
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands As Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease
Ppardelta Mediates the Effect of Dietary Fat in Promoting Colorectal Cancer Metastasis
Exploration and Development of PPAR Modulators in Health and Disease: an Update of Clinical Evidence
Peroxisome Proliferator-Activated Receptors
Peroxisome Proliferator-Activated Receptors
Seladelpar (MBX-8025), a Selective PPAR-Δ Agonist, in Patients with Primary Biliary Cholangitis with an Inadequate Response To
The Role of Lipid Sensing Nuclear Receptors (Ppars and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD
WO 2018/193007 Al 2018/193007
Update on New Drugs and Those in Development for the Treatment of Primary Biliary Cholangitis
Potential Treatment for Duchenne Muscular Dystrophy (DMD) † † † † † Bharat Lagu,*, Arthur F
Exploration and Development of PPAR Modulators in Health and Disease : an Update of Clinical Evidence
Bioactive Compound Library Plus (96-Well)
Top View
Co-Incubation with Pparβ/Δ Agonists and Antagonists Modeled Using Computational Chemistry: Effect on LPS Induced Inflammatory Markers in Pulmonary Artery
Inventiva S.A
The Pennsylvania State University
Modelling the Effects of Pparβδ of Innate Inflammatory Responses in Lung Tissues
Hépatite Auto-Immune
Review Article: the Impact of Liver‐Directed Therapies on The
Peroxisome Proliferator-Activated Receptors and Their Novel Ligands As Candidates for the Treatment of Non-Alcoholic Fatty Liver
Drug Repurposing Compound Library Plus (96-Well)
Cymabay Is Out, but for Genfit the Band Plays On
(Spparmα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel?
Statins, Fibrates, and Other Peroxisome Proliferator-Activated Receptor Agonists for the Treatment of Cholestatic Liver Diseases
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Articles Seladelpar (MBX-8025), a Selective PPAR-Δ Agonist, In
Distinct but Complementary Contributions of PPAR Isotypes to Energy Homeostasis
Developing Breakthrough Therapies in NASH and MPS
Modelling the Effects of Pparβδ of Innate Inflammatory Responses In
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
A Triple Farnesoid X Receptor and Peroxisome Proliferator-Activated
WO 2018/193006 Al 25 October 2018 (25.10.2018) W !P O PCT